Abattis Completes Acquisition of Remaining Minority Interest in Gabriola Green Farms

Vancouver, British Columbia--(Newsfile Corp. - April 30, 2018) - Abattis Bioceuticals Corp. (the "Company" or "Abattis") (CSE: ATT / OTC: ATTBF) is pleased to announce, further to its news release dated April 18, 2018, that it has completed its acquisition of the remaining 10% ownership interest (the "Interest") in its subsidiary, Gabriola Green Farms Inc. ("Gabriola"). Abattis acquired the Interest from CannaNUMUS Blockchain Inc. for $2.5 million. Gabriola is now a wholly-owned subsidiary of the Company.

About Abattis Bioceuticals Corp.

Abattis is a life sciences and biotechnology company which aggregates, integrates, and invests in cannabis technologies and biotechnology services for the legal cannabis industry developing in Canada. The Company has successfully developed and licensed natural health products, medicines, extractions, and ingredients for the biologics, nutraceutical, bioceutical, and cosmetic markets. The Company is also seeking to acquire exclusive intellectual property rights to agricultural technologies to be employed in extraction and processing of botanical ingredients and compounds. The Company follows strict standard operating protocols and adheres to the applicable laws of Canada and foreign jurisdictions. For more information, visit the Company's website at: www.abattis.com.

ON BEHALF OF THE BOARD OF ABATTIS BIOCEUTICALS CORP.,

"Rob Abenante"
Robert Abenante, President & CEO

For more information, please visit the Company's website at: www.abattis.com or www.northernvinelabs.com

For inquiries, please contact the Company at (604) 674-8232 or at news@abattis.com.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAS REVIEWED OR ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.